Active Ingredient(s): Cladribine
FDA Approved: * February 26, 1993
Pharm Company: * ORTHO BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Leustatin Overview

Cladribine, sold under the brand names Leustatin among others, is a medication used to treat hairy cell leukemia (HCL, leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia.[5][6] Oral Cladribine (Cladribine tablets), sold under the brand name MAVENCLAD, is indicated for the treatment of adult patients with highly active forms of relapsing-remitting multiple sclerosis (RRMS).[7] Cladribine (2-chloro-2'-deoxyadenosine [2-CdA]) i...

Read more Leustatin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cladribine

Recent Leustatin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 1mg/ml
  • Tablet: 10mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Leustatin: (1 result)

Sorted by National Drug Code
  • 59676-201 Leustatin 1 mg/ml Intravenous Injection, Solution by Janssen Products, L.p.

Other drugs which contain Cladribine or a similar ingredient: (2 results)